News
ALVR
0.7502
+1.09%
0.0081
Weekly Report: what happened at ALVR last week (0408-0412)?
Weekly Report · 5d ago
Weekly Report: what happened at ALVR last week (0401-0405)?
Weekly Report · 04/08 09:02
Allovir, Inc.: Report of proposed sale of securities
Press release · 04/03 04:09
Weekly Report: what happened at ALVR last week (0325-0329)?
Weekly Report · 04/01 09:02
Weekly Report: what happened at ALVR last week (0318-0322)?
Weekly Report · 03/25 09:02
Maintaining a Hold: AlloVir’s Strategic Uncertainty and Financial Outlook
TipRanks · 03/19 05:35
ALVR Stock Earnings: AlloVir Misses EPS for Q4 2023
AlloVir reported earnings per share of -53 cents for the fourth quarter of 2023. The company did not report any revenue for the quarter. This was below the analyst estimate for EPS of -43 cents. AlloV Vir reported results for the last quarter of 2013.
Investorplace · 03/18 19:53
Weekly Report: what happened at ALVR last week (0311-0315)?
Weekly Report · 03/18 09:02
ALVR DEADLINE TUESDAY: ROSEN, A LEADING LAW FIRM, Encourages AlloVir, Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – ALVR
Rosen Law Firm reminds purchasers of securities of AlloVir, Inc. Of the important March 19, 2024 lead plaintiff deadline. A class action lawsuit has already been filed against the company. If you purchased securities during the Class Period, you may be entitled to compensation.
Barchart · 03/17 19:00
Weekly Report: what happened at ALVR last week (0304-0308)?
Weekly Report · 03/11 09:02
Weekly Report: what happened at ALVR last week (0226-0301)?
Weekly Report · 03/04 09:02
SHAREHOLDER ALERT: Potential Recovery for AlloVir, Inc. (ALVR) Investors
TipRanks · 03/01 00:01
Weekly Report: what happened at ALVR last week (0219-0223)?
Weekly Report · 02/26 09:02
Class Action Filed Against AlloVir, Inc. (ALVR) Seeking Recovery for Investors - Contact Levi & Korsinsky
Barchart · 02/20 04:45
Weekly Report: what happened at ALVR last week (0212-0216)?
Weekly Report · 02/19 09:02
AlloVir Faces Delisting Risk, Considers Reverse Split to Comply
TipRanks · 02/12 21:43
Weekly Report: what happened at ALVR last week (0205-0209)?
Weekly Report · 02/12 09:02
ALLOVIR INVESTOR ALERT: Kirby McInerney LLP Notifies AlloVir, Inc. (ALVR) Investors of Upcoming Lead Plaintiff Deadline in Class Action Lawsuit
A class action lawsuit has been filed in the U.S. District Court for the Massachusetts on behalf of those who acquired AlloVir, Inc. Securities. Investors have until March 19, 2024 to apply to be appointed as a lead plaintiff in the lawsuit. In December 2023, Allovir announced it was discontinuing studies of its lead product posoleucel.
Barchart · 02/12 05:00
Allovir Inc <ALVR.OQ> expected to post a loss of 43 cents a share - Earnings Preview
Allovir Inc expected to post a loss of 43 cents a share - Earnings Preview. The company is expected to show change in quarterly revenue when it reports results on February 13. LSEG's mean analyst estimate is for Allovir to report a quarterly loss of 43 cents per share.
Reuters · 02/09 14:01
We Think AlloVir (NASDAQ:ALVR) Needs To Drive Business Growth Carefully
AlloVir's (NASDAQ:ALVR) cash burn relative to its market cap is 168% of the company's market value. The company's cash burn has reduced by 9.3% over the last year, but is still high enough to be a risk. We look at whether shareholders should be worried about AlloVirs cash burn. Allovir has a long runway for growth, but we think its cash burn is a risk for shareholders. We have also identified 6 warning signs for Allo vir that you should be aware of.
Simply Wall St · 02/09 10:27
More
Webull provides a variety of real-time ALVR stock news. You can receive the latest news about Allovir, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About ALVR
AlloVir, Inc. is an allogeneic T cell immunotherapy company with a focus on restoring natural immunity against life-threatening viral diseases in pediatric and adult patients with weakened immune systems. The company’s proprietary technology platforms leverage off-the-shelf, allogeneic, single- and multi-virus-specific T cells for patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. Its technology and manufacturing process enable the potential for the treatment and prevention of a spectrum of devastating viruses with each single allogeneic cell therapy. Its lead product candidate, posoleucel, is a multi-VST therapy that targets six viruses: adenovirus (BKV), cytomegalovirus (EBV), human herpesvirus 6 (HHV-6) and JC virus (JCV). Its proprietary VST manufacturing platform enables the rapid, robust and reproducible generation of single-virus and multi-virus specific cell therapeutic candidates for clinical use.